Olmesartán Pensa Pharma (Olmesartan Medoxomil)

Olmesartan medoxomil selectively blocks AT1 receptors, preventing angiotensin II from causing vasoconstriction and aldosterone secretion. This results in relaxed blood vessels, reduced fluid retention, and a subsequent decrease in systemic blood pressure.

The appropriate dose of Olmesartán Pensa Pharma is determined by the prescribing healthcare professional based on the individual’s blood pressure response, renal function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Olmesartan medoxomil is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy. Limited data are available for breastfeeding; therefore, it is generally recommended to avoid use while nursing unless the benefit outweighs the potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Olmesartan belongs to the ARB class, offering blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than directly relaxing vascular smooth muscle.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in bathrooms or other humid environments.

Olmesartán Pensa Pharma is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include angioedema, which can cause swelling of the face, lips, tongue, or throat, and acute renal impairment, especially in patients with pre‑existing kidney disease. Hyperkalemia is another critical concern, particularly when combined with potassium‑sparing agents.

Patients who are pregnant, have known hypersensitivity to olmesartan or any component of the formulation, or have severe renal artery stenosis should avoid this medication. Caution is also advised for individuals with severe hepatic impairment or a history of angioedema.